Publications by authors named "Maureen Vanlancker"
Background: Standard treatment for patients with newly diagnosed glioblastoma includes surgery, radiotherapy (RT), and temozolomide (TMZ) chemotherapy (TMZ/RT→TMZ). The proteasome has long been considered a promising therapeutic target because of its role as a central biological hub in tumor cells. Marizomib is a novel pan-proteasome inhibitor that crosses the blood-brain barrier.
View Article and Find Full Text PDFBackground: Myelosuppression is the major toxicity encountered during temozolomide chemoradiotherapy for newly diagnosed glioblastoma.
Methods: We assessed the association of myelosuppression (neutropenia, thrombocytopenia, anemia, and lymphopenia) during temozolomide chemoradiotherapy alone or in combination with experimental agents with progression-free survival (PFS) or overall survival (OS) in 2073 patients with newly diagnosed glioblastoma enrolled into five clinical trials: CENTRIC, CORE, EORTC 26082, AVAglio, and EORTC 26981. A landmark Cox model was used.
Article Synopsis
- Monalizumab is a type of medicine that helps boost our immune cells to fight certain cancers, especially in the head and neck.
- In a study called UPSTREAM, doctors tested how well monalizumab worked for patients with a specific kind of cancer after other treatments didn't work.
- The results showed that while some patients had stable cancer for a short time, the medicine didn't really help most of them, so doctors are now looking at combining it with another treatment for better results.
Medulloblastoma is a rare brain malignancy. Patients after puberty are rare and bear an intermediate prognosis. Standard treatment consists of maximal resection plus radio-chemotherapy.
View Article and Find Full Text PDF